---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-275466"
form_type: "8-K"
ticker: "CGEM"
cik: "0001789972"
company_name: "Cullinan Therapeutics, Inc."
filed_at: "2022-11-02T23:59:59+00:00"
generated_at: "2026-06-22T14:59:36.537104+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# David P. Ryan appointed to board; Ansbert Gadicke resigns as director at Cullinan Oncology

## Summary
- David P. Ryan, M.D. appointed as Class II director effective Nov 1, 2022.
- Dr. Ryan brings over 20 years of oncology experience; Clinical Director at MGH Cancer Center since 2012.
- Received option grant with $250,000 fair value, vesting one-third annually over three years.
- Ansbert Gadicke, M.D. resigned as director effective Nov 1, 2022; no disagreement with Company.
- Dr. Ryan appointed to Compensation Committee.

## SEC filing metadata
- accession: 0001193125-22-275466
- form_type: 8-K
- ticker: CGEM
- cik: 0001789972
- company_name: Cullinan Therapeutics, Inc.
- filed_at: 2022-11-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789972/000119312522275466/0001193125-22-275466-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789972/000119312522275466/d332832d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-275466
- JSON: https://secwatch.observer/filing/0001193125-22-275466.json
- Plain text: https://secwatch.observer/filing/0001193125-22-275466.txt

## Key facts
- Executive change
  Ansbert Gadicke resigned as director at Cullinan Therapeutics, Inc..
  - Action: resigned
  - Role: director
  source text: Ansbert Gadicke, M.D. notified the Board of his intention to resign as a director effective as of November 1, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1789972/000119312522275466/0001193125-22-275466-index.htm
- Executive change
  David P. Ryan was appointed as Class II director at Cullinan Therapeutics, Inc..
  - Action: appointed
  - Role: Class II director
  source text: appointed David P. Ryan, M.D. as a Class II director, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1789972/000119312522275466/0001193125-22-275466-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.